Key facts
- This page summarizes Sofia Touami's Form 3 filing for Lycia Therapeutics, Inc..
- 0 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 22 Oct 2026, 19:16.
Key filing fact
Ownership activity is grounded in SEC Form 3 disclosures.
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
No transaction description listed
No transaction description listed
No transaction description listed
Additional SEC filing notes
Footnote F1
The options vested as to 1/4 of the total award on July 10, 2024, and an additional 1/48 of the total award will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Footnote F2
The options vested as to 1/48 of the total award on July 27, 2024, and an additional 1/48 of the award will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Footnote F3
The options vested as to 1/48 of the total award on September 6, 2026, and an additional 1/48 of the award will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.